Trials / NCT03116113
A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112
Completed Phase 1 / Phase 2 Gene therapy
- Sponsor
- Biogen
- Treatment
- BIIB112
- Gene
- RPGR
- Conditions
- X-Linked Retinitis Pigmentosa
- Ages
- 10 Years to no upper limit
- Enrollment
- 50 participants
- Started
- 2017-03-08
- Main results expected
- 2020-11-18
- Results posted
- Yes
- Record last updated
- 2024-01-18
What the study is testing
The objective of the study is to evaluate the safety, tolerability and efficacy of a single sub-retinal injection of BIIB112 in participants with X-linked retinitis pigmentosa (XLRP).
Where it runs
United Kingdom (3)
- Research Site, Manchester
- Research Site, Oxford
- Research Site, Southampton
United States (5)
- Research Site, Gainesville, Florida
- Research Site, Miami, Florida
- Research Site, Portland, Oregon
- Research Site, Philadelphia, Pennsylvania
- Research Site, Dallas, Texas